RE:RE:RE:RE:RE:RE:RE:RE:RE:Deliberate Obfuscation LS29 ... The market is tanking. Nothing related to TLT.
We all know we're advancing toward something interesting and pivotal if data continues a positive trend. Management has brought us here, on the verge of a projected Breakthrough designation late 2022 and projected commercial revenues early 2023, so being impatient won't change anything. They know more than us and the recent buying of Roger and Kristina should calm you as at this time, it's more than a positive signal, given all they know about the clinical data of Ph. 2b patients.
This pullback is just another of those many golden opportunities to add more if you so believe in this stock.